Children treated with mepolizumab during asthma flare-ups showed a significant reduction in eosinophil-driven type 2 (T2) ...

Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...

A distinct inflammatory profile marked by neutrophil activity and cytokine elevation may underline poor biological response ...

CHICAGO — In this Healio video, Evan S. Dellon, MD, MPH, explains that while mepolizumab outperformed placebo at 3 months, there were no additional symptom or endoscopic improvements at 6 ...

PHOENIX -- Adding mepolizumab (Nucala) to guideline-based care reduced flare-ups in disadvantaged kids with exacerbation-prone, eosinophilic asthma, the yearlong MUPPITS-2 trial showed.

Mepolizumab and benralizumab had similar safety profiles for patients with severe eosinophilic asthma despite their different mechanisms, according to a study published in The Journal of Allergy ...

Mepolizumab is also approved for use in three other eosinophilic driven diseases, the first indication being for patients with severe eosinophilic asthma aged six years and older.